Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 70Neoplasms 13Neoplasm Metastasis 7Brain Neoplasms 7Head and Neck Neoplasms 6Breast Neoplasms, Male 6Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Osteitis Deformans 2Neuroma, Acoustic 2Neurofibromatosis 2 2Inflammatory Breast Neoplasms 2Glioblastoma 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2

Interventions

ganitumab 2conatumumab 1cixutumumab 1Paclitaxel 1Lapatinib 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Insulin-Like Growth Factor I, Resistance To × Lapatinib × Clear all
NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
64 enrolled 13 charts
Breast

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡